JP2025507958A5 - - Google Patents

Info

Publication number
JP2025507958A5
JP2025507958A5 JP2024552401A JP2024552401A JP2025507958A5 JP 2025507958 A5 JP2025507958 A5 JP 2025507958A5 JP 2024552401 A JP2024552401 A JP 2024552401A JP 2024552401 A JP2024552401 A JP 2024552401A JP 2025507958 A5 JP2025507958 A5 JP 2025507958A5
Authority
JP
Japan
Prior art keywords
rna
nucleic acid
sequence
targeting
acid molecule
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024552401A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025507958A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2023/063798 external-priority patent/WO2023168458A1/en
Publication of JP2025507958A publication Critical patent/JP2025507958A/ja
Publication of JP2025507958A5 publication Critical patent/JP2025507958A5/ja
Pending legal-status Critical Current

Links

JP2024552401A 2022-03-04 2023-03-06 操作された核内低分子RNA(snRNA)を含む組成物および方法 Pending JP2025507958A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202263316659P 2022-03-04 2022-03-04
US63/316,659 2022-03-04
US202263379983P 2022-10-18 2022-10-18
US63/379,983 2022-10-18
PCT/US2023/063798 WO2023168458A1 (en) 2022-03-04 2023-03-06 Compositions and methods comprising engineered small nuclear rna (snrna)

Publications (2)

Publication Number Publication Date
JP2025507958A JP2025507958A (ja) 2025-03-21
JP2025507958A5 true JP2025507958A5 (cg-RX-API-DMAC7.html) 2026-03-09

Family

ID=85792399

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024552401A Pending JP2025507958A (ja) 2022-03-04 2023-03-06 操作された核内低分子RNA(snRNA)を含む組成物および方法

Country Status (10)

Country Link
US (3) US20230279397A1 (cg-RX-API-DMAC7.html)
EP (1) EP4486888A1 (cg-RX-API-DMAC7.html)
JP (1) JP2025507958A (cg-RX-API-DMAC7.html)
KR (1) KR20240164824A (cg-RX-API-DMAC7.html)
CN (1) CN119137273A (cg-RX-API-DMAC7.html)
AU (1) AU2023228712A1 (cg-RX-API-DMAC7.html)
CA (1) CA3245423A1 (cg-RX-API-DMAC7.html)
IL (1) IL315378A (cg-RX-API-DMAC7.html)
MX (1) MX2024010833A (cg-RX-API-DMAC7.html)
WO (1) WO2023168458A1 (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230279397A1 (en) 2022-03-04 2023-09-07 Locanabio, Inc. Compositions and methods comprising engineered short nuclear rna (snrna)
EP4605529A1 (en) 2022-10-18 2025-08-27 Regeneron Pharmaceuticals, Inc. Compositions and methods comprising programmable snrnas for rna editing
CN120548368A (zh) 2022-12-01 2025-08-26 再生元制药公司 用于正确包装重复元件的腺相关病毒载体
EP4784751A2 (en) 2023-09-26 2026-08-05 Regeneron Pharmaceuticals, Inc. Compositions and methods comprising small nuclear rna (snrna) for treating dmd
WO2025090628A1 (en) 2023-10-23 2025-05-01 Regeneron Pharmaceuticals, Inc. Compositions and methods comprising small nuclear rna (snrna) for treating genetic epilepsies
IL328914A (en) 2023-12-15 2026-08-01 Regeneron Pharmaceuticals Inc Compositions and methods comprising small nuclear RNA (snRNA) targeting SOD1
WO2025160364A2 (en) 2024-01-26 2025-07-31 Regeneron Pharmaceuticals, Inc. Compositions and methods comprising small nuclear rna (snrna) for the treatment of pompe disease
WO2026090560A1 (en) * 2024-10-25 2026-04-30 Crank Bio, Inc. Engineered nucleic acids and uses thereof

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1283876B1 (it) 1996-01-12 1998-05-07 Univ Roma Molecole chimeriche ribozima-snrna ad attivita' catalitica per rna a localizzazione nucleare
US5814500A (en) 1996-10-31 1998-09-29 The Johns Hopkins University School Of Medicine Delivery construct for antisense nucleic acids and methods of use
US6692910B2 (en) 1997-07-28 2004-02-17 The University Of Connecticut Inhibition of a target messenger RNA with a modified U1 small nuclear RNA
JP2004514407A (ja) 2000-04-28 2004-05-20 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア 異種キャプシド中にシュードタイピングされたaav5キャプシドおよびaav5ベクターを含む組換えaavベクター
EP1384784A1 (en) 2001-03-30 2004-01-28 Instituto Cientifico Y Tecnologico De Navarra, S.A. Method for reversible inhibition of gene expression by modified ribonucleoproteins
ITRM20020253A1 (it) 2002-05-08 2003-11-10 Univ Roma Molecole chimeriche di snrna con sequenze antisenso per le giunzioni di splicing del gene della distrofina e applicazioni terapeutiche.
FR2874384B1 (fr) 2004-08-17 2010-07-30 Genethon Vecteur viral adeno-associe pour realiser du saut d'exons dans un gene codant une proteine a domaines dispensables
US8822168B2 (en) 2005-03-11 2014-09-02 The Trustees Of The University Of Pennsylvania Assays for detecting small nuclear ribonucleoprotein particle assembly and survival of motor neurons activity
US9040491B2 (en) 2006-08-30 2015-05-26 The Trustees Of The University Of Pennsylvania Compositions, methods and kits based on small nuclear RNAs
US9441221B2 (en) 2007-03-30 2016-09-13 Rutgers, The State University Of New Jersey Compositions and methods for gene silencing
EP2142672B1 (en) 2007-03-30 2012-09-05 Rutgers, The State University of New Jersey Compositions and methods for gene silencing
US8343941B2 (en) 2007-03-30 2013-01-01 Rutgers, The State University Of New Jersey Compositions and methods for gene silencing
US8907075B2 (en) 2007-03-30 2014-12-09 Samuel Ian Gunderson Compositions and methods for gene silencing
DK2623605T3 (en) 2007-04-09 2019-03-25 Univ Florida RAAV VECTOR COMPOSITIONS WITH TYROSIN MODIFIED CAPSIDE PROTEINS AND PROCEDURES FOR USE THEREOF
ES2566553T3 (es) * 2010-03-17 2016-04-13 Association Institut De Myologie ARNnp U7 modificados para el tratamiento de las enfermedades neuromusculares
IT1400425B1 (it) 2010-06-08 2013-05-31 Amsterdam Molecular Therapeutics Bv Modified snrnas for use in therapy.
IT1405793B1 (it) 2010-10-15 2014-01-24 Univ Ferrara Molecola di u1snrna umano modificato, gene codificante per la molecola di u1snrna umano modificato, vettore di espressione includente il gene, e loro uso in terapia genica
US9303258B2 (en) 2011-04-05 2016-04-05 The Regents Of The University Of California Method and compositions comprising small RNA agonist and antagonists to modulate inflammation
US9862945B2 (en) 2013-04-20 2018-01-09 Research Institute At Nationwide Children's Hospital Recombinant adeno-associated virus delivery of exon 2-targeted U7SNRNA polynucleotide constructs
CA2957661A1 (en) 2014-08-09 2016-02-18 Kevin FLANIGAN Methods and materials for activating an internal ribosome entry site in exon 5 of the dmd gene
US9669109B1 (en) 2015-11-24 2017-06-06 Universita Di Ferrara Modified human U1snRNA molecule, a gene encoding for the modified human U1snRNA molecule, an expression vector including the gene, and the use thereof in gene therapy of familial dysautonomia and spinal muscular atrophy
FR3044926B1 (fr) 2015-12-09 2020-01-31 Genethon Outils de therapie genique efficaces pour le saut de l'exon 53 de la dystrophine
JP6966463B2 (ja) 2016-02-26 2021-11-17 リサーチ インスティチュート アット ネイションワイド チルドレンズ ホスピタル 組換えウイルス産物及びdux4エクソンスキッピングを誘導するための方法
AU2019326551A1 (en) 2018-08-22 2021-03-18 Research Institute At Nationwide Children's Hospital Recombinant virus products and methods for inhibiting expression of dystrophia myotonica protein kinase and/or interfering with a trinucleotide repeat expansion in the 3' untranslated region of the DMPK gene
JP2022524383A (ja) 2019-03-08 2022-05-02 ラトガース,ザ ステート ユニバーシティ オブ ニュー ジャージー ハンチントン病を処置するための組成物および方法
JP2022520885A (ja) 2019-03-26 2022-04-01 ラトガース,ザ ステート ユニバーシティ オブ ニュー ジャージー 神経変性疾患を処置するための組成物および方法
WO2020214763A1 (en) * 2019-04-18 2020-10-22 Sarepta Therapeutics, Inc. Compositions for treating muscular dystrophy
EP4004204A1 (en) 2019-07-23 2022-06-01 Oxford BioMedica (UK) Limited Enhancing production of lentiviral vectors
US20220282247A1 (en) 2019-08-02 2022-09-08 Research Institute At Nationwide Children's Hospital Exon 44-targeted nucleic acids and recombinant adeno-associated virus comprising said nucleic acids for treatment of dystrophin-based myopathies
IL293671A (en) 2019-12-09 2022-08-01 Astellas Pharma Inc Antisense guide RNA with an additional functional region for target RNA editing
CA3173012A1 (en) * 2020-04-22 2021-10-28 Susan BYRNE Compositions and methods using snrna components
US20240261434A1 (en) 2020-09-28 2024-08-08 Research Institute At Nationwide Children's Hospital Products and methods for treating muscular dystrophy
CA3203585A1 (en) 2020-11-30 2022-06-02 Research Institute At Nationwide Children's Hospital Compositions and methods for treating facioscapulohumeral muscular dystrophy (fshd)
AU2022262420A1 (en) 2021-04-23 2023-11-16 Research Institute At Nationwide Children's Hospital Products and methods for treating muscular dystrophy
US20230279397A1 (en) 2022-03-04 2023-09-07 Locanabio, Inc. Compositions and methods comprising engineered short nuclear rna (snrna)

Similar Documents

Publication Publication Date Title
US11920132B2 (en) Oligonucleotide therapy for Leber congenital amaurosis
GB2625500A (en) Engineered CasX repressor systems
EP3277816B1 (en) Crispr/cas-related methods and compositions for treating duchenne muscular dystrophy and becker muscular dystrophy
CN104245935B (zh) 三环硫代磷酸酯dna
JP2022534809A5 (cg-RX-API-DMAC7.html)
JP2020513811A5 (cg-RX-API-DMAC7.html)
JP2022529631A5 (cg-RX-API-DMAC7.html)
JP2019513393A5 (cg-RX-API-DMAC7.html)
CA3097857A1 (en) Fusion proteins and fusion ribonucleic acids for tracking and manipulating cellular rna
US12037588B2 (en) Compositions and methods comprising engineered short nuclear RNA (snRNA)
WO2020142714A1 (en) Aav expression cassette and aav vectors comprising the same
JP2023551873A5 (cg-RX-API-DMAC7.html)
JP2007532130A5 (ja) マイクロrna及びそれを阻害する医薬品
JP2019515663A5 (cg-RX-API-DMAC7.html)
JP2022553573A5 (cg-RX-API-DMAC7.html)
JP2022522166A5 (cg-RX-API-DMAC7.html)
JP2024517607A5 (cg-RX-API-DMAC7.html)
JP2024073525A5 (cg-RX-API-DMAC7.html)
JP2025513066A5 (cg-RX-API-DMAC7.html)
WO2006017522A2 (en) Use of antisense oligonucleotides to effect translation modulation
WO2020144611A4 (en) Double stranded rna and uses thereof
JP2021524730A5 (cg-RX-API-DMAC7.html)
JP2022508835A5 (cg-RX-API-DMAC7.html)
RU2021123042A (ru) Двухнитевая рнк и варианты ее применения
KR20260029512A (ko) 안정성이 개선된 삼중나선 구조의 핵산 분자 및 이의 용도